Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Veterinary Dermatology Drugs Market

Veterinary Dermatology Drugs Market Share

Report ID: GMI6332
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Veterinary Dermatology Drugs Market Share

There are several significant competitors in the highly competitive veterinary dermatology drugs companies. The prominent players are

Elanco Animal Health Incorporated
Vetoquinol S.A.
Ceva
Merck & Co., Inc.
Zoetis, Inc.
Virbac
Bimeda, Inc.
Vivaldis
Bioiberica S.A.U
Indian Immunologicals Ltd.

To keep a competitive advantage in the market, such companies are putting various tactics into practice, including partnerships, mergers, acquisitions, collaborations, and product launches.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The veterinary dermatology drugs industry size was valued to be USD 7.3 billion in 2022 and is expected to record a CAGR of 9.5% from 2023 to 2032 owing to the rising incidence of skin disorders in animals.

The oral segment was worth USD 3.4 billion in 2022 and is expected to grow at 9.2% CAGR through 2032 as this route of administration provides a systemic approach to dermatological disorders, allowing the medication to circulate through the body and address the underlying source of the problem.

North America veterinary dermatology drugs market is expected to reach USD 6.9 billion by 2032 as the region has a significant number of veterinary dermatology specialists who focus on diagnosing and treating skin conditions in animals.

Elanco Animal Health Incorporated, Vetoquinol S.A., Ceva, Merck & Co., Inc., Zoetis, Inc., Virbac, Bimeda, Inc., Vivaldis, Bioiberica S.A.U, and Indian Immunologicals Ltd.